UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number: 001-40128 biote Corp. (Exact Name of Registrant as Specified in its Charter) Delaware 85-1791125 (State ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.23 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.10, delivering a surprise of 11.11%. There are no easy answers to this key quest ...

biote Corp (BTMD) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Company Participants Szymon Serowiecki - Senior Associate - IRBret Christensen - CEORobert Peterson - Chief Financial OfficerKaumil Gajrawala - Managing DirectorLes Sulewski - VP - Biotech Equity ResearchJonna Kim - Director Conference Call Participants Jeff Van Sinderen - Senior AnalystGeorge Kelly - Managing Director, Senior Research Analyst Operator Hello, and welcome to the Biodi First Quarter twenty twenty five Earnings Conference Call. A ...

biote Corp (BTMD) Q1 2025 Earnings Call May 07, 2025 05:00 PM ET Speaker0 Hello, and welcome to the Biodi First Quarter twenty twenty five Earnings Conference Call. All participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Simon Sarovietki. Please go ahead. Speaker1 Thank you for joining us today. This afternoon, Bati published financial results for the fir ...

Biote Reports First Quarter 2025 Financial Results Strong financial performance driven in part by increased gross margin from vertical integration Announces organizational restructuring to drive sustainable growth and build long-term value Maintains 2025 financial outlook First Quarter 2025 Financial Highlights • Revenue of $49.0 million IRVING, TX – May 7, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therap ...

Revenue Growth - Revenue for the year ended December 31, 2024, was $197.2 million, up from $185.4 million in 2023, representing a growth of approximately 9.7%[37] - The compound annual growth rate (CAGR) for procedure revenue from 2019 to 2024 was 8.9%[37] - The total U.S. market opportunity for hormone replacement therapy (HRT) products is estimated to exceed $7 billion, with an expected annual growth rate of 7% through 2026[25] Market Opportunity - Approximately 20 million men over age 45 in the U.S. are affected by hypogonadism, with only about 10 million (12%) undergoing testosterone treatment[26] - An average of 27 million women between the ages of 45 and 64 experience menopause annually, yet only 28% (approximately 13 million) undergo HRT[26] Practitioner Engagement - Biote-certified practitioners have performed approximately five million hormone optimization procedures, with over 400,000 active patients as of December 31, 2024[29] - The retention rate among Biote-certified practitioners is over 95% as of December 31, 2024[33] - Biote has contracted with over 8,600 practitioners who have adopted the Biote Method in their practices[33] Product Offerings - Biote-branded dietary supplements represent approximately 18% of annual revenues, with an average supplement volume per practice of approximately $9,100 as of 2024[47] - The company has expanded its product offerings to include 24 dietary supplements since 2013, with prices ranging from $9.46 to $50.45[60] - Biote's dietary supplement business has grown at an 11.5% CAGR from 2019 to 2024[93] Revenue Sources - The service fees generated from hormone replacement therapy (HRT) procedures utilizing pellets accounted for approximately 76% of total revenue in 2024[71] - Biote-branded dietary supplement sales accounted for approximately 18% of total revenue in 2024, with 76% of partnered clinics offering these products[60] Operational Infrastructure - The company employs a 123-person sales force to attract new practitioners and support existing clinics, enhancing overall productivity[73] - The company has developed a comprehensive platform that includes education, training, and practice management tools specifically for hormone optimization[42] - As of December 31, 2024, Biote has contracted with over 8,600 certified practitioners across more than 4,700 partnered clinics, with 900 new clinics added in 2024, contributing to 66% of revenue growth[68] Compliance and Regulatory Environment - The healthcare regulatory landscape is complex and subject to rapid changes, which may impact the company's operations and compliance[119] - The company is subject to various federal and state healthcare regulations, including the Health Insurance Portability and Accountability Act (HIPAA), which mandates the protection of sensitive patient health information[164] - The company must navigate complex state and federal healthcare fraud and abuse laws, which could result in fines and restrictions on its operations if violated[159] Market Challenges - The hormone replacement therapy market is highly competitive, with over 30 brands in the dietary supplement space, posing challenges for market penetration and share[195] - Future revenue growth could slow or decline due to increasing competition and market saturation, impacting profitability[202] - The company faces risks related to potential violations of federal and state healthcare laws, which could lead to legal and financial repercussions[209] International Expansion - The company plans to expand operations into new international markets, including Argentina, Brazil, Colombia, and Canada, which will involve significant resources and management attention[221] - Expansion into new markets may face regulatory, economic, and political risks, including localization of the platform and compliance with local data privacy laws[222] Employee and Practitioner Relations - The company is highly dependent on key personnel, and losing any of them could severely disrupt operations and growth prospects[204] - Attracting and retaining contracts with Biote-certified practitioners and clinics is crucial for maintaining business and brand image[205] Financial Reporting and Structure - Biote Holdings, LLC completed a business combination with Haymaker Acquisition Corp. III, resulting in the formation of biote Corp. on May 26, 2022[172] - The company operates under an umbrella partnership-C corporation (Up-C) structure, which may have implications for its financial reporting and tax obligations[172] Supply Chain and Inventory Management - The company has increased its safety stock for dietary supplements from three weeks to four weeks due to global supply chain disruptions[109] - The reliance on third-party manufacturers for dietary supplements entails risks, including potential inventory shortages and compliance issues, which could adversely affect the company's operations[182]

biote Corp. (NASDAQ:BTMD) Q4 2024 Earnings Conference Call March 12, 2025 5:00 PM ET Corporate Participants Szymon Serowiecki - Investor Relations Mark Beard - Executive Chairman Bret Christensen - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Jeff Van Sinderen - B. Riley George Kelly - ROTH Capital Partners Alex Fuhrman - Craig-Hallum Capital Group Operator Good day, and welcome to the Biote Fourth Quarter 2024 Earnings Conferen ...

Provides fiscal 2025 outlook IRVING, TX – March 12, 2025 - Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Full Year 2024 Financial Highlights Exhibit 99.1 Biote Reports Fourth Quarter and ...

Company Performance - biote Corp. (BTMD) has returned approximately 28.5% year-to-date, significantly outperforming the average loss of 2.4% in the Medical sector [4] - The Zacks Consensus Estimate for BTMD's full-year earnings has increased by 46.2% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [4] - biote Corp. is currently ranked 2 (Buy) in the Zacks Rank system, which focuses on earnings estimates and revisions [3] Industry Context - biote Corp. is part of the Medical - Products industry, which consists of 87 companies and is currently ranked 80 in the Zacks Industry Rank [6] - The Medical - Products industry has seen an average gain of about 11.4% year-to-date, with biote Corp. outperforming this group [6] - In contrast, the Medical Services industry, which includes another outperforming stock, Doximity (DOCS), is ranked 132 and has declined by 12.3% year-to-date [6][5]

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the ...